DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intravitreal Avastin in Proliferative Retinopathies

Information source: Ophthalmological Association Edelweiss
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Retinal Neovascularization

Intervention: Avastin (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Ophthalmological Association Edelweiss

Official(s) and/or principal investigator(s):
NARCISA IANOPOL, researcher, Principal Investigator, Affiliation: Ophthalmological Association Edelweiss

Summary

The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes

Clinical Details

Official title: Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes

Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The following parameters will be assessed in order to evaluate the Avastin effect: visual acuity, lesions's area at the ocular fundus

Secondary outcome: The intraocular pressure will be measured during the whole study in order to assess the possible side effects of Avastin injections

Detailed description: Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments. Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR

DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc)

- distance acuity < 0. 5

- age > 20 years

Exclusion Criteria:

- noncooperative patients

- ocular infections / inflammations

Locations and Contacts

Ochiul Diabetic, Iasi 700377, Romania
Additional Information

Starting date: July 2007
Last updated: July 20, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017